D652-Kowshik Kumar M
D652-Kowshik Kumar M
D652-Kowshik Kumar M
Submitted by
M.D.
In
DERMATOLOGY, VENEREOLOGY AND LEPROSY
I
B. L. D. E. UNIVERSITY’s
research work carried out by me under the guidance of DR. ARUN C. INAMADAR.,
University‟s Shri B. M. Patil Medical College Hospital and Research Centre, Vijayapur.
Place: Vijayapur
II
B. L. D. E. UNIVERSITY’s
bonafide research work done by Dr. KOWSHIK KUMAR M in partial fulfillment of the
III
B. L. D. E. UNIVERSITY’s
KUMAR M under the guidance of DR. ARUN C. INAMADAR, Professor and HOD,
Date: Date:
Place: Vijayapur Place: Vijayapur
IV
B. L. D. E. UNIVERSITY’s
COPYRIGHT
I hereby declare that the BLDE University, Karnataka shall have the rights to
preserve, use and disseminate this dissertation / thesis in print or electronic format for
Place: Vijayapur
V
ACKNOWLEDGEMENT
With proud privilege and deep sense of respect I express my gratitude and
indebtedness to my guide and esteemed teacher Dr. Arun. C. Inamadar M.D, D.V.D,
Adya, Asst Prof, Dr. Ajit Janagond Asst Prof, and Dr. N. S. Deshmukh, senior
Gopal M and Mrs Gayathri Devi M who are the pillars of my strength and
VI
I would like to thank my seniors Dr Ajay Mujja, Dr Sneha Manjunath,
I express my thanks to the Mrs Shamshad, Mr Dalawai and all other hospital
My special thanks to Mr. Babu Patil “Om Sai Internet”, Vijayapur for
This dissertation would not have been possible without the co-operation and
Place: Vijayapur
VII
LIST OF ABBREVIATIONS
2. DP : Dermal papilla
3. DHT : Dihydrotestosterone
16. FT : frontotemporal
17. BA : Basic
18. SP : Specific
22. NE : Nanoemulsions
VIII
24. PRGF : Plasma rich in growth factors
IX
ABSTRACT
pattern of progressive hair loss. Dermal papilla (DP) is the site of expression of
various hair growth related genes. According to various studies Wnt proteins and
alopecia.
Materials and method: Sixty eight men with grade III and IV androgenetic alopecia
(AGA) were recruited into 2 groups. After randomization one group was offered
weekly microneedling treatment with twice daily 5% minoxidil lotion (study group);
other group was given only 5% minoxidil lotion (control group). Baseline global
photographs were taken. Dermoscopic images were taken from a 1 cm targeted fixed
area at baseline and at end of therapy (week 12) from where hair count was done. The
2 primary efficacy parameters assessed were: Increase from baseline hair count at 12
weeks and patient self assessment of hair growth at 12 weeks. Two blinded
Patient‟s self perception regarding hair growth was assessed by 10 inch long visual
analogue scale.
X
Results: (1) Hair counts – The mean increase in hair count at week 12 was
significantly greater for the study group compared to the control group (12.52 vs 1.89
respectively). (2) Patient evaluation – In the study group, 4 (12.9%) patients reported
minoxidil treated group in promoting hair growth in men with AGA for 2 primary
significant. However, the total number and frequency of sessions and long-term
XI
TABLE OF CONTENTS
1 INTRODUCTION 1-2
2 OBJECTIVES 3
4 METHODOLOGY 34-42
5 RESULTS 43-52
6 DISCUSSION 53-56
7 CONCLUSION 57-58
8 SUMMARY 59-60
9 BIBLIOGRAPHY 61-64
10 ANNEXURES 65-74
ETHICAL CLEARANCE
PROFORMA
MASTER CHART
XII
LIST OF TABLES
XIII
LIST OF FIGURES
1. Hair cycle 5
8. Pull test 20
9. Trichoscopy 21
11 Dermoscope 37
used
XIV
15b Global photograph, After 12 weeks(control subject) 41
XV
INTRODUCTION
obsessed modern society, not only women but even men are very conscious
finasteride) in AGA that is based on both preventing hair loss and promoting
hair re- growth, varies between 30% and 60%. Unfortunately about 40% of men
with AGA remain or go bald despite being on conventional therapy. This has led
growth with the current therapies, who needs better cosmetic coverage over the
scalp.2
Topical Minoxidil and oral Finasteride are the only two currently
approved drugs by Food and Drug Administration [USA] for treatment of AGA
The dermal papilla (DP) is a cluster of specialized fibroblasts that regulate the
growth and activity of the various cells in the follicle, thereby, it plays an important
role in the regulation of hair cycle and growth. Regeneration of hair follicle starts
1
when signals from the mesenchyme derived DP cells reach multipotent epidermal
DP's capillaries, then bind to the androgen receptor on the DP cells and further
activate or repress molecular signalling pathways which are responsible for premature
AGA involves not only DHT but also inflammation, many genes, signalling pathways
(stimulatory pathways like Wnt/B catenin, stat 3 and Shh and inhibitory pathways of
Dkk‑1, BMP 4 and Dickkopf‑related protein 1), growth factors, activation of stem
cells of the hair bulge and improving vascularity. The existing conventional therapies
(i.e. finasteride and minoxidil) fail to target all of the above mechanisms as they
Study done by Dhurat et al.3 in humans has shown that microneedling is a safe,
effective and also a promising tool in hair growth stimulation when used along
augments the hair growth induced by minoxidil. Hence, this study is undertaken
2
OBJECTIVE OF THE STUDY
3
REVIEW OF LITERATURE
common cause of hair loss over scalp in men. The term androgenetic alopecia was
Psychosocially, men with AGA have the tendency to have low self-
esteem, distant peer relationships and might even suffer from depression as it
Epidemiology:
men develop AGA by the age of 50.4 AGA can affect all races, but with variable
that prevalence rates in Caucasian populations is around 30% for men in their 30s,
40% in their 40s and 50% in their 50s.5 In the Indian context, a study done on clinical
pattern of AGA in 150 subjects showed a peak incidence of 48% in males aged 15-
24years.1
cycle [figure 1]. The active growth phase (anagen) lasts for 3-5 years. At the end
of anagen, there is a brief stage of regression known as catagen which lasts for
few weeks. This is followed by a period of hair follicle quiescence and lasts
4
approximately 3 months known as telogen. The catagen phase is a process of
This results in an upward movement of dermal papillae. In the telogen phase the shaft
of hair matures into a club (vellus) hair. Eventually the hair sheds as a result of
cycle, while the length of telogen phase remains constant or is prolonged. This
phase determines the length of the hair, the maximum length of the new anagen hair
becomes shorter than that of its predecessor. The result is a progressive and gradual
5
A) Genetics 5:
prevalence and the wide range of expressed phenotypes in AGA. The genes
The two major loci of genetic risk for AGA are the X chromosome
The AR gene regulates the potency of androgen available to the hair follicle.
There are many known AR gene polymorphisms. Among them the Stu 1 gene
Several other genes (5α reductase, aromatase, estrogen receptor α and IGF-2
genes) have been identified where associations could not be proved conclusively.
Dermal papilla plays a key role in the maintenance and control of hair
in many skin tissues. Testosterone penetrate the cell membrane freely and is
converted to DHT by 5 α reductase (mainly Type II) in the cytoplasm. DHT binds
6
to androgen receptor (AR) and this complex is translocated to the nucleus. This
results in target gene transcription and finally translation into genes which exerts
biological activity.5,7
The dermal papillae under the influence of androgens secretes many factors,
which unfolds the interaction between dermal papillae and the hair follicle cells.
These factors released from dermal papillae have an autocrine effect on the dermal
papillae itself and paracrine effect on the hair follicle epithelial cells. These
factors include growth factors like insulin like growth factor (IGF-1), basic
cytokines like transforming growth factor beta 1 (TGF-β1), interleukin 1 alpha (IL
7
The signaling process which occurs at the interface of dermal papillae and hair
was found to be one of the most upregulated genes by DHT, resulting in inhibition
In a balding scalp, the concentration of important factors such as, DHT along
with 5 α reductase and AR‟s are increased. The other enzymes which show an
and androgen receptor, more the effect on expression of genes which control
follicular cycling.5
properties required for hair follicle regeneration and hair shaft growth. The
androgens and ligand activated AR can hamper the Wnt/β catenin signalling
8
Clinical features and grading:
scalp and leads to baldness. Patients have a reduction in the terminal-to- vellus
hair ratio.
Patients with AGA show hair loss in a typical distribution. Preferentially three
areas of the scalp are affected : the temples, vertex scalp and mid frontal scalp.
The process is strictly patterned within these areas. Hair loss over the bitemporal
areas starts at the anterior hair line and moves posteriorly over the scalp. Hair
loss over the vertex scalp begins centrally and radiates outwards circumferentially.4
[figure 3].
9
meatus on both sides. Hair is either lost or sparse along the mid-
IIIv (vertex) Hair is mainly lost in the vertex. There may be some frontal
recession but it does not exceed than that seen in type III.
IV The frontal and FT recession is more severe than type III. There
bald areas are extensive, but separated from each other by a band
V The hair loss over the vertex and FT areas is larger than in type
VI The hair loss over the FT and vertex regions is confluent and
10
Type variants „a‟ Constitutes 3% of all cases of male AGA: (i) the entire
IIa The entire anterior border of the hairline lies high on the forehead.
IVa The area of denudation extends beyond the mid-coronal line, there
line.
11
Figure 3: Norwood-Hamilton classification of AGA
recessions and frontal thinning, which consisted of eight evolutionary aspects and
Type I: There is an absence of bilateral recessions along the anterior hairline in the
frontoparietal regions. Type IA is a variant form in which the entire anterior hairline
12
Type II: The anterior hairline in the frontoparietal regions has symmetrical triangular
line drawn in a coronal plane between the external auditory meatuses. Hair is also
lost, or sparse, along the midfrontal border of the scalp but the depth of the affected
Type III: Borderline cases were included separately as Type III. This list also included
denudation, unusual types of sparseness and thinning of the hair, and other factors.
There are deep frontotemporal recessions, usually symmetrical, and are either bare or
very sparsely covered by hair. These recessions extend farther posteriorly than a
point, which lies 3 cm anterior to a coronal line drawn between the external auditory
meatuses. Type IVA is a variant in which hair is sparse or lacking as a broad band
Type VI: The tonsural region of alopecia remains separated from more anteriorly
located areas of hair loss by a laterally-directed bar of scalp in which the hair is only
slightly sparse. An island of hair lies in the midline anterior to this laterally-directed
hairy bridge. In the Type VIA variant, the peninsula or island of mid-frontal hair is
sparse or lost.
Type VII and VIII: In these types, the horseshoe-shaped area of sparse hair or of hair
13
result of the spread and confluence of the tonsural and the anteriorly located regions
of alopecia.
used as it was difficult to apply and needs taking multiple measurements in every
14
Figure 5: Blanchard classification of hair loss
In this classification, the male patterned baldness is classified into six subtypes
by the English alphabetical letter shape of the bald area [Figure 6]. The various
A) Type M: Both sides of the frontotemporal hairlines look triangular or like the letter
M.
B) Type C: The anterior hairline looks like a half-circle or the letter C. Both M and C
C) Type O: There is a round or ovoid denuded patch on the vertex or occiput while
D) Type U: Recession of the anterior hairline progresses over the vertex, which looks
15
E, F) Types MO and CO: When recession of the frontotemporal hairline exists, with a
denuded patch on the vertex, as combined patterns, these are types MO and CO,
16
Basic and specific classification (BASP) 5,10 :
which is irrespective of sex [figure:7]. Broadly, classified into basic and specific
types. The basic (BA) types denote the shape of the anterior hairline, and the specific
types (SP) correspond to the density of hair on distinct areas (frontal and vertex).
There are four basic types (L, M, C, and U) and two specific types (F and V).
The final type is decided by the combination of the assigned basic and specific
types. The basic types are classified by the English alphabetical letter shape of the
Type L – No hair line recession is observed along the anterior border in the
the mid-anterior hairline. The hairline resembles the English alphabetical letter shape
M.
Type C – More prominent recession in the mid-anterior hairline is seen than the
Type U – The entire anterior hairline regresses posteriorly beyond the vertex forming
Type F – This indicates a generalised decrease in the hair density over the entire
scalp, not considering the type of anterior hairline. It is usually more marked over the
frontal scalp
Type V – More distinct hair loss is seen in the vertex scalp than in the frontal area.
17
Figure 7: BASP classification of hair loss
18
Management:
1) Diagnosis 5:
a) History:
hair loss like telogen effluvium. The typical history in all patients of AGA in
men is long duration of hair loss with thinning mainly over the frontal, parietal
within the last one year should be taken. Usually family history is positive for
AGA.
The scalp is generally normal in AGA, but factors that worsen the
condition like seborrheic dermatitis should be ruled out. The pattern of hair
c) Pull test 6:
hairs are grasped between the thumb, the index and middle fingers. The hairs
are then gently but firmly pulled. A negative test (six or less hairs/less than
10% obtained) point toward normal shedding, whereas a positive test (more
than six hairs or 10% obtained) indicates definite and active hair shedding.
Shampooing should not be done for 24 hrs prior to a pull test. In patients with
AGA the test is generally negative except in the active phase and that too only
in the affected sites like the frontal area. A diffusely positive pull test all over
the scalp hints the possibility of other diagnosis like telogen effluvium.
[figure 8]
19
Figure 8: Pull test
d) Trichoscopy5 :
seen in AGA.
20
Yellow dots
Thinning of hair
e) Scalp biopsy 5:
taken from the centre of the most affected areas. Sampling from the
bitemporal area are better avoided as this area usually have miniaturized hairs
taken ideally – one for transverse sectioning and the other for horizontal
greater than 7:1, while in AGA it is generally less than 3:1. Other main
perifollicularly with or without mild fibrosis around the upper part of the
follicle.
21
f) Global photography 5:
patient with clean, dry hair and a technician who is able to take the time to
comb and prepare the hair exactly the same way at each clinical visit. The
patient should also be advised to maintain the same hair style and color as of
the first visit. Multiple photograph should be taken covering all scalp areas.
The four basic views usually preferred are the vertex, mid-pattern, frontal, and
image with respect to magnification, position and lighting which can be best
22
2) Treatment:
Topical Systemic
-Hair transplantation:
Minoxidil 2%-5% 5-Alpha -Laser therapy
reductase - Strip
Tretinoin 0.025% -Supportive therapy:
inhibitors : harvesting
Azelaic acid 5%
- Follicular
Ketoconazole 2% unit - Wigs
Finasteride
Fluridil harvesting
Medical management:
Minoxidil: Since 1960s, oral minoxidil has been used to treat hypertension.
to the development of topical minoxidil as a treatment for hair loss. FDA has
23
Proposed Mechanisms of action:5,6
papillae.
follicular levels of PGE2 resulting in the prolongation of anagen phase and the
growth promoter.
solutions, foams and gels. Both 5% and 10% solutions are currently in use for
treatment in males.4 Human studies have shown that minoxidil increases hair count,
linear growth and also diameter of hair. The increase in hair count is usually evident
face.6 Itching of scalp, increased scaling and erythema may be seen.4 Irritant and
allergic contact dermatitis may also occur, most commonly due to propylene glycol
treatment of alopecia. Fang et al, has reported the development of squarticles, which
24
are nanoparticles formed from sebum-derived lipid such as squalene and fatty esters.
These are used in attaining targeted drug delivery to the follicles. Two different
vivo.12
enzyme 5-alpha-reductase converts testosterone to its active form DHT. Two types of
5-alpha-reductase are seen in humans. Type I predominates in the liver, skin and scalp
while type II is mainly seen in prostate, genitourinary tract and the hair follicle. Drugs
reductase-inhibitor while dutasteride, inhibits both type I and type II iso enzymes.5
of AGA is 1 mg daily in male patients above 18 years with mild to moderate AGA.
Oral dutasteride 0.5 mg daily is another option, but only few studies are available to
study.13
humans and animals have shown that the combination of minoxidil 5% and oral
Combining hair transplant with oral finasteride is also considered to be superior than
hair transplant alone. Main concern while treating male patients for AGA with oral
finasteride are sexual side effects.5 Long term studies have reported rare adverse
25
effects of erectile dysfunction in 1.4% and loss of libido is observed in 1.9% of
26
a study by Navarro et al., intradermal injection of plasma rich in growth
factors (PRGF) into the scalp is a safe and effective treatment for AGA and
also shows that PRGF exerts improved anagen/telogen results than topical
minoxidil alone.19
Surgical treatments:
and sides of the scalp and reimplantation into the bald vertex and frontal scalp.
Horse shoe shaped (horizontal) area in the occipital region is considered as a „safe
donor area‟.5
removed from the occipital scalp under local anaesthesia, and the wound
is then sutured back together. The donor hair is then divided into separate
follicular units which is transplanted into the balding area. The main
disadvantage in this technique is that, the wound heals with a linear scar in
from occipital scalp under local anaesthesia with 1mm punch biopsies. Each
unit is then reinserted back into the balding scalp using a microblade. In this
method, there are no visible scars seen after healing as single follicular
harvesting.4,5,20,21
- Combination of two : In this, a strip is marked out on the scalp. FUE method
is then used to remove follicular units from above and below the marked strip
27
of scalp. The advantage in this method is more number of grafts can be
Scalp flap and scalp reduction surgeries are not frequently used at present as a
Laser therapy:
A variety of laser and light sources have been tried for treatment of hair
loss, with varied success. The mechanism of low-level lasers on hair growth is
AGA.5
an acrylate polymer (CNDPA) has shown to increase the hair fiber diameter which
Future developments:
The use of bio-engineered hair follicles derived from stem cells has found to
be effective in animal studies and in future this could be a definite option for
AGA.5, 24
In vitro studies have demonstrated good results with copper peptides, but at
28
Topical valproic acid and hair stimulating complex (HSC) acts via Wnt/β-
(GP4G), biotin, zinc, omega 3 fatty acids and antioxidants , topical caffeine,
Microneedling:
superficial and controlled puncturing of the skin by rolling with miniature fine
needles.
Basic instrument:
circular arrays of 192 fine microneedles, usually 0.5–3 mm in length and 0.1–
Principle :
bleeding and set up a wound healing cascade with release of various growth
factors such as platelet derived growth factor (PDGF), TGF-α and TGF-β,
29
connective tissue activating protein, connective tissue growth factor, and
Activation of stem cells in the hair bulge area under wound healing
Wnt10 b.
1. Skin rejuvenation
5. Stretch marks
Topical tretinoin and vitamin C for the treatment of acne scarring and
skin rejuvenation.
androgenetic alopecia.
30
Enhances the effect of 5-aminolevulinic acid for more efficacious
Contraindications 26:
1. Active acne
6. Patient on chemo/radiotherapy.
In a Study by Jeong et al.27 10 mice were divided into 5 groups and each
group dorsal skin was depilated. Disktype roller was applied to each group
mm, 0.25 mm, 0.5 mm, 1.0 mm. After obtaining microneedle length for hair
growing, most effective rolling cycle determining experiment was carried out
to know hair follicle status and its related growth factors. Microneedling
stimulation group have shown the enhanced expression of hair related genes and
stimulation of hair .
31
In a study by Kim et al.28 mice were divided into seven groups: negative
groups showed earlier and faster hair growth than untreated mice group. Also,
the hair induced by microneedle roller was shinier than the hair induced by
RT-PCR.
In a study by Dhurat et al.3 100 men with AGA were divided into
microneedling group and minoxidil group, with 50 members in each group. All
patients scalp was shaved off before treatment to ensure equal length of hair
four of the 100 patients completed the 12 week study period of which 50 were
evident that it is a safe and a promising tool in hair stimulation for male
pattern baldness and also is useful to treat hair loss refractory to minoxidil
32
therapy. Moreover microneedling is a non expensive procedure which is affordable
to all class of patients. The side effects of microneedling procedure are negligible.
33
METHODOLOGY
SOURCE OF DATA :
A hospital based prospective and single observer blinded study was conducted in the
Patil Medical College Hospital and Research Centre, Vijayapur. Sixty eight male
patients with AGA were recruited for the study. The study was conducted during the
Age matched (± 5 years) male patients of age group 18 years to 40 years with AGA
grade III and IV were enrolled for the study. 34 patients each were taken as cases and
controls.
Inclusion criteria:
1. Male patients of 18 - 40 years age group with AGA grade III and IV.
Exclusion criteria:
34
6. Patients with history of psoriasis or lichen planus because of the risk of
Koebner phenomenon.
Methods:
Detailed history with respect to the onset and duration of hair loss, any
Initial clinical examination of the patient was done by one of the investigators
These findings were recorded in the proforma (first visit record). Informed consent for
Sixty eight cases of AGA grade III and IV were allocated randomly into
'study' (N = 34) and 'control' (N = 34) groups based on patients feasibility for weekly
follow-up. Each patient was studied for 12 weeks. Patients in the 'study' group were
applied twice daily. Patients in the control group were given only 5% minoxidil
solution 1ml for twice daily application for a period of 12 weeks. Baseline clinical
Microneedling was done for the patients in the 'study' group weekly for 4
sessions initially, and thereafter fortnightly for subsequent 4 sessions, covering the
total duration of 12 weeks. Post treatment clinical photographs were taken at the
35
Methodology:
Equipments:
with a drum-shaped roller attached to it at one end (Figure 10). The drum-
shaped roller is studded with 192 microneedles in eight rows, 1.5mm in length
scalp area. For this study dermaroller (ReGe Roller system) manufactured by
ii. Video Dermoscope : It is a portable and versatile hand held device which has a
high resolution and triple light source (normal light, ultraviolet light,
polarization light) at one end (figure 11). It has a possibility for connecting to
the computer and view the images. For hair-count at baseline and follow-up
36
Figure 11: Video dermoscope
Hair count calculation: The test area on scalp in both study and control groups,
undertaken for hair count was decided as follows: one square inch area on the vertex
with thinning of hair was selected for each patient. The distance of this area on all
sides (anteriorly from glabella, posteriorly from occiput, and laterally from the tips of
both the ear helices) was measured and recorded in proforma for reproducing during
follow up. This area was defined and marked using a skin marking pencil at baseline
and again during follow up. The square area was divided into 4 equal quadrants by a
vertical and a horizontal lines (Figure 12). Digital images were taken from each
quadrant separately using the video dermoscope at baseline and at the end of 12
weeks. Hair count was done by two investigators on computer screen at magnification
37
Figure 12: Measurements of the test area on vertex to be used for hair count
Microneedling procedure :
The scalp was cleaned with betadine and normal saline. A dermaroller of
needle size 1.5 mm was rolled over the affected areas of the scalp in a longitudinal,
vertical, and diagonal directions until mild erythema is noted, which was considered
as the end point of the procedure. All patients were instructed not to apply minoxidil
on the day of procedure and to resume its application only 24 hours after the
microneedling procedure. The patients were also instructed to apply minoxidil on dry
scalp and not to use any other hair oil while using minoxidil.
FOLLOW -UP:
Patients in both the groups were followed up for a period of 12 weeks. The
patients in 'study' group were asked to come for next microneedling session weekly
for first 4 consecutive weeks and thereafter for every 2 weeks for a period of 8 weeks.
The patients in the 'control' group were asked to come for routine visit for every 4
weeks for a period of 12 weeks. During each visit, the findings related to treatment
38
response like decrease in hair fall, appearance of new hair and patients' general
perception regarding the treatment were recorded. Any adverse effects related to
therapy was recorded in the proforma at each visit. At the end of 12 weeks the final
EFFICACY EVALUATION:
i) Increase from baseline hair count at 12 weeks (done by the investigators as per
above protocol).
ii) Patient self assessment of hair growth at 12 weeks; patients in both the groups
were asked to mark their perception regarding hair growth on a 10 inch long 'visual
0 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
39
STATISTICAL ANALYSIS:
Clinico-epidemiological data collected from the patients were compared using paired
and unpaired t-test, Wilcoxon match pairs test, Mann Whitney U test , chi square test.
Mean ± SD and diagrammatic presentation of these values were used to present the
data.
ETHICAL CLEARANCE:
40
Figure 14a and 14b are the clinical photographs showing grade 3 response on 10-inch
visual analog scale in a patient of study group. Figure 15a and 15b are the clinical
control group.
Baseline
41
Figure 16a and 16b are Dermoscopic pictures showing grade 3 response on 10-inch
visual analog scale in a patient of study group. Figure 17a and 17b are the
42
RESULTS
A hospital based prospective and single observer blinded study was conducted
from November 2015 to May 2017. A total of sixty eight male patients with
androgenetic alopecia were included in the study. They were randomly allocated into
Age Distribution :
The age of the patients enrolled in the study group ranged from 18 to 38 years.
The mean age (± SD) of the study population was 27.53 (± 5.142) years. The age of
the patients enrolled in the control group ranged from 18 to 34 years. The mean age (±
SD) of the control group was 24.56 (± 3.386) years. The maximum number of patients
were in the age group 23 to 26 years in both the groups. Figure 7 presents the age
43
Age of onset of hair loss:
The age of onset of hair loss of the patients enrolled in the study group ranged
from 18 to 32 years. The mean age (± SD) of onset of hair loss of the study population
was 23.56 (± 3.295) years. The age of onset of hair loss of the patients enrolled in the
control group ranged from 14 to 30 years. The mean age (± SD) of onset of hair loss
The duration of hair loss of the patients enrolled in both the groups ranged
from 6 months to 10 years. The mean duration (± SD) of hair loss of the study
population was 49.62 (± 37.979) months. The mean duration (± SD) of hair loss of the
control group was 31.71 (± 29.526) months. The duration of hair loss in maximum
number of patients in both groups was less than 1.8 years. Figure 8 presents the
distribution of the patients according to duration of hair loss of both study and control
groups.
44
Previous treatment history:
History of receiving treatment in the past for AGA was present in 21(30.8%)
in control group. Figure 9 presents the distribution of the patients according to history
Family history:
groups. In study group 16 (47%) had family history of AGA compared to 14 (41.2%)
patients in control group. Figure 10 presents the distribution of the patients according
45
Figure 10: Distribution of patients based on family history of AGA
In study group 11 (32.4%) had grade IV hair loss, followed by grade IIIv (vertex) type
in 7(20.6%), grade IVa (anterior) in 6 (17.6%) and grade III and IIIa (anterior) type
in 5 (14.7%) patients each. In control group 11 (32.4%) had grade IV hair loss,
followed by grade III type in 8(23.5%), grade IIIv (vertex) in 6 (17.6%), grade III a
distribution of the patients according to AGA grade in both study and control groups.
46
Figure 11: Distribution of patients according to AGA grade
Among 68 patients who were enrolled in the study, 60(88.23%) patients have
completed the study at the end of 12 weeks. Eight (11.76%) patients were lost to
follow-up. Three patients in study group and five patients in control group were lost
to follow-up and they were not considered for efficacy evaluation. So, 31 out of 34 in
study group and 29 out of 34 patients in control group were considered for efficacy
evaluation.
patients.
47
The mean (±SD) patient self assessment of hair growth at the end of 12 weeks
study on a visual analogue scale was 2.97±1.28 and 1.21±0.90 in study and control
groups respectively which is statistically significant (p < 0.0001*). The patient‟s self
assessment of hair growth at the end of 12 weeks has been presented in table 2 and 3.
0 1(3.2) 7(24.1)
1 3(9.7) 11(37.9)
2 6(19.4) 9(31)
3 11(35.5) 2(6.9)
4 6(19.4) 0
5 4(12.9) 0
48
Hair count:
Increase from baseline hair count at 12 weeks was a primary efficacy variable.
The mean(± SD) hair count in study group at baseline was 82.35(± 22.56) and at the
end of 12 weeks is 94.87 (± 22.82) . The mean(± SD) hair count in control group at
baseline was 80.37(± 16.48) and at the end of 12 weeks is 82.27 (±14.72). All
subjects of study group have shown increase in target area hair count over 12 weeks
ranging from 1 to 30. No increase in target area hair growth was noted in 7 (24.1%)
in control group over 12 weeks. The mean increase in hair count at week 12 was
significantly greater for study group compared to control group (12.82 Vs. 1.89
respectively, p < 0.0001). Increase from baseline hair count at week 12 has been
(week 12)
49
Table 5: Increase in hair count at week 12
received treatment in the past when compared to patients who has not received
between history of previous treatment and increase in hair count at week 12 has been
50
Table 7: Association between treatment history and increase in hair count in
study group
control group
Therapy related side effects noted in study group were mild pain during
5% solution after 12 weeks of therapy. They were also informed to come for monthly
follow up. However, only few patients of study group have continued minoxidil 5 %
51
application and are on follow up. Patients in the study group who continued using
Some of the patients who have followed up after the last session of microneedling,
but stopped minoxidil application have not maintained the response that was
52
DISCUSSION
hair loss which worsens over time without treatment. As healthy hair is important
for the young and attractive appearance of individual in this modern world, the
treatment have been proposed and used. No treatment modality is curative. Hair
therapy and is not maintained after treatment discontinuation. The efficacy of any
modality of treatment varies depending upon the age of the patient, grade of hair loss,
compliance with treatment. Minoxidil and finasteride are the only FDA approved
treatment modalities for AGA whose efficacy varies between 30% and 60%.3 As per
various studies, men with AGA using minoxidil monotherapy continue to go bald
despite on therapy.
Dermal papillae plays a key role in the regulation of hair cycling and
re-growth.25,26
Based on studies in mice, Jeong et al. 25and Kim et al.26 suggested that micro
needle roller could be useful tool to treat hair loss which is refractory to minoxidil
53
A total of 68 patients were recruited in the present study, 60 of whom
completed the treatment duration of 12 weeks. Three patients in the study group and
five patients in the control group were lost to follow-up. In similar study by Dhurat et
al3, ninety four out of 100 patients completed the 12 week study, of which 50 were
treated with both microneedling and 5% minoxidil solution and 44 were treated with
We have included patients in the age range of 18-40 years whereas in the
Dhurat et al. subjects were in the age group of 20 and 35 years. However the mean
age of the population in study group was 27.53 years and in the control group was
24.56 years which were similar to findings in Dhurat et al. study (28.6 years). We
have also modified our methodology by not making scalp shaving compulsory for the
procedure, so that more patients can be included in the study. In the current study,
patients had hair loss for a mean average duration of 4.1 years in study group and 2.6
years in control group, which was comparable to Dhurat et al. study (4.5 years).
In the present study, 17 subjects having grade III vertex and grade IV hair loss
each in microneedling (study) group. Similarly, in the control group 20 had grade III
vertex and 14 had grade IV hair loss where as in Dhurat et al. study 23 had grade III
vertex and 27 had grade IV hair loss in microneedling group and 21 had grade III
vertex and 23 had grade IV hair loss in the minoxidil group. Twenty one of our
subjects had received some form of treatment in the past, whereas 20 had been
treated with finasteride and minoxidil in the past without any improvement in Dhurat
et al. study.
microneedling group versus only 2 (4.5%) in the minoxidil group on patient self
54
assessment of hair growth at week 12 in the Dhurat et al. study, whereas only 4
In the pilot study by Dhurat et al., the mean increase in hair count at week 12
was significantly greater for the microneedling group compared to the minoxidil
group (91.4 vs. 22.2 respectively, p = 0.039). In our study, the mean (±SD) increase in
hair count at the end of 12 weeks, was 12.51(±6.82) in study group and 1.89 (±8.94)
in control group which is significant (p<0.0001). Even though the change in hair
much less when compared with Dhurat et al. study. Comparison of mean increase in
In our study, 10 patients in the study group reported mild pain during
microneedling procedure but it was tolerable. There was no significant adverse effect
55
From the above discussion it is evident that microneedling is an effective,
safe and promising therapeutic modality for the treatment of AGA along with topical
group of patients, though statistically superior to response in the control group, is not
cosmetically significant when compared to Dhurat et al. study. Most plausible reasons
for this finding may be due to difference in the procedures adopted for evaluating the
increase in hair count and also by not making scalp shaving compulsory for the
subjects. However, the sample size is small and short follow-up period is short in both
the studies. Though the response achieved by microneedling in hair growth in our
minoxidil even after the study period. This finding is similar to conventional
the response.
56
CONCLUSION
Progressive hair loss occurs in AGA patients which worsens over time if not
treated. Treatment is required to prevent further baldness and also to promote new
hair growth.
Conventional modalities of treatment are not able to target all these factors. None of
the medical therapeutic modalities available for AGA to date is completely curative.
The efficacy of FDA approved minoxidil and finasteride for AGA varies between
30% and 60%. Long-term treatment is required to achieve the response and life-long
AGA. Hence it can show augmented response when combined with conventional
modalities of treatment.
Out of 34 subjects in each group, only 4(12.9%) in the study group and none
in the control group have reported 50 % improvement in hair growth on patient self
assessment scale. The mean increase in hair count at week 12 was significantly
greater for the subjects in the microneedling group compared to the minoxidil only
group (12.5 vs.1.25 respectively, p< 0.0001). However, the response achieved in
minoxidil.
57
No therapy related side effects were noted in the control group. Subjects in
the study group have reported mild pain during and after microneedling procedure
which is tolerable.
The results of this study did not establish „microneedling combined with
minoxdil‟ as a unique therapeutic modality for male AGA. However the study had a
small sample size and limited follow-up of the patients. However, the total number
58
SUMMARY
minoxidil alone in male AGA was conducted during the period of November 2015 to
May 2017. Male patients of 18 - 40 years age group with AGA grade III and IV were
the study subjects. 34 patients each were included in study and control groups.
Patients in the 'study' group were offered 'microneedling' treatment on scalp along
subjects were given only 5% minoxidil solution 1ml for twice daily application for a
period of 12 weeks. Response to treatment in the form of increase in hair count and
patient‟s self assessment of hair growth were evaluated at the end of 12 weeks.
The mean age (± SD) of the subjects in study and the control group was 27.53
The mean age (± SD) of onset of hair loss of the subjects in study and the
control groups was 23.56 (± 3.295) years and 21.71 (± 3.398) years
respectively.
59
The mean increase in hair count at week 12 was 12.82 Vs. 1.89 for study and
microneedling.
60
BIBLIOGRAPHY
http://www.ncbi.nlm.nih.gov/books/NBK278957/.
6. Dhurat R, Sukesh MS. Hair and scalp disorders. In: Sacchidanand S, Oberai
androgen action in cultured dermal papilla cells derived from human hair
61
8. Kwack MH, Sung YK, Chung EJ, Im SU, Ahn JS, Kim MK, Kim JC.
262-269.
9. Kwack MH, Kang BM, Kim MK, Kim JC, Sung YK. Minoxidil activates β-
catenin pathway in human dermal papilla cells: a possible explanation for its
12. Fang JY, Shen FM, Huang CT. Squarticles as a nanocarrier for targeting
minoxidil to hair follicles and dermal papilla cells. J Derm Sci. 2016;
84:e59.
62
pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad
Dermatol 2012;66:794–800.
18. Zimber MP, Ziering C, Zeigler F, Hubka MDC, Jonathan N, Mansbridge JN,
2011;10:13081312.
19. Navarro MR, Asín M, Martínez MA, Martínez AM, Molina C, Moscoso L,
comparative clinical study between plasma rich in growth factors and topical
20. Shiell RC. A review of modern surgical hair restoration techniques. J Cutan
21. Rose PT. The latest innovations in hair transplantation. Facial Plast Surg.
2011; 27:366-377.
22. Avram MR, Leonard Jr RT, Epstein ES, Williams JL, Bauman AJ. The
current role of laser/light sources in the treatment of male and female pattern
63
23. Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH.
27. Jeong K, Lee YJ, Kim JE, Park YM, Kim BJ, Kang H. Repeated
28. Kim BJ, Lim YY, Kim HM, Lee YW, Won CH, Huh CH, et al. Hair follicle
2012;4:117.
64
ANNEXURES
65
B.L.D.E.U’s SHRI B M PATIL MEDICAL COLLEGE HOSPITAL AND
PURPOSE OF RESEARCH:-
I have been informed that this project will be studied to measure the
BENEFITS:-
therapy.
PROCEDURE:-
I understand that relevant history will be taken and I will undergo detailed
required.
66
CONFIDENTIALITY:-
part of my hospital records and will be subjected to the confidentiality and privacy
regulation of the said hospital. Information of a sensitive personal nature will not be a
part of the medical records, but will be stored in the investigator‟s research file.
If the data are used for publication in the medical literature or for teaching
purposes no names will be used and other identifiers such as photographs and audio or
videotapes will be used only with my special written permission. I understand I may
see the photographs, videotapes and hear the audiotapes before giving this permission.
or may withdraw consent and discontinue participation in this study at any time
participation in this study at any time after she has explained the reasons for doing so
and has helped arrange for my continued care by my own physician, if this is
appropriate.
INJURY STATEMENT:-
my participation in this study and if such injury were reported promptly, then medical
67
I have explained to (patient‟s / relevant guardian‟s name) the purpose of the
research, the procedures required, and the possible risks and benefits to the best of my
guide / chief researcher ) has explained to me the research, the study procedures that I
undergo and the possible risks and discomforts as well as benefits that I may
experience. I have read and I understand this consent form. Therefore, I agree to give
________________________ ________________________
________________________ ________________________
68
PROFORMA
Name: SL NO:
Age: Date:
Occupation:
Address:
1. Chief complaints:
69
2. Presenting features :
4. family history:
5. Past history:
History of surgery/stress:
70
Any anti-coagulant medication:
7. Cutaneous examination:
71
Measurements of the test area on vertex to be used for hair count:
72
8. Systemic Examination
Cardiovascular system :
Respiratory system :
Abdominal examination :
9. Diagnosis:
73
B.L.D.E.U’S SHRI B. M. PATIL MEDICAL COLLEGE HOSPITAL AND
0 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
74